[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628866":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":11,"centralContacts":11,"locations":29,"responsibleParty":48,"collaborators":11,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":11,"enrollmentInfo":60,"targetDuration":11,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":70,"overallStatus":32,"whyStopped":11,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Samsung Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Routine Potassium Competitive Acid Blocker Group","EXPERIMENTAL",null,[13],"Drug: Zastaprazan",{"label":15,"type":16,"description":11,"interventionNames":17},"Guideline-Directed Gastrointestinal Protection Group","ACTIVE_COMPARATOR",[18],"Drug: Proton Pump Inhibitors (PPI)",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Zastaprazan","Zastaprazan citrate 20mg will be administered orally once daily for gastrointestinal protection according to the study protocol.",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Proton Pump Inhibitors (PPI)","Guideline-directed gastrointestinal protection using various proton pump inhibitors as determined by the physician.",[15],[30],{"facility":31,"status":32,"city":33,"state":11,"zip":34,"country":35,"countryCode":11,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Samsung Medical center","RECRUITING","Seoul","06351","South Korea",{"type":37,"coordinates":38},"Point",[39,40],126.9784,37.566,{"lat":40,"lon":39},[43],{"name":44,"role":45,"phone":46,"phoneExt":11,"email":47},"Jooyoung Hahn","CONTACT","+82 02-3410-6653","jinshil6.kim@sbri.co.kr",{"type":49,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100628866","phase-3-routine-use-of-potassium-competitive-acid-blocker-vs-guideline-directed-gastrointestinal-protection-strategy-in-acute-myocardial-infarction-100628866",false,"NCT07467213","Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction","Routine Use of Potassium Competitive Acid Blocker Versus Guideline-Directed Gastrointestinal Protection Strategy in Patients With Acute Myocardial Infarction Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy: A Randomized Trial","PCAB-AMI","Inclusion Criteria:\n\n* Patients aged 19 years or older.\n* Patients diagnosed with acute myocardial infarction (ST-segment elevation myocardial infarction \\[STEMI\\] or non-ST-segment elevation myocardial infarction \\[NSTEMI\\]).\n* Patients who underwent percutaneous coronary intervention (PCI) with drug-eluting stents (DES) or drug-coated balloons (DCB).\n* Patients (or their legal representatives) who understood the study risks and benefits and provided voluntary written informed consent.\n\nExclusion Criteria:\n\n* History of hypersensitivity (e.g., allergic reaction, anaphylactic shock) or contraindication to study drugs (potassium-competitive acid blocker \\[P-CAB\\] or proton pump inhibitor \\[PPI\\]).\n* Presence of active gastrointestinal bleeding.\n* Pregnant or breastfeeding women.\n* Non-cardiac life expectancy of less than 1 year or patients expected to have low compliance (as determined by the investigator's medical judgment).\n* Patients who refuse to participate or are unable to follow the requirements specified in the study protocol.","ALL","19 Years",{"count":61,"type":62},5000,"ESTIMATED","INTERVENTIONAL",[65],"PHASE3","This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).",[68,69],"Acute Myocardial Infarction (AMI)","Gastrointestinal Bleeding",[71,72,73,22],"Percutaneous Coronary Intervention","Dual Antiplatelet Therapy","Potassium Competitive Acid Blocker","2026-06-23",{"date":76,"type":77},"2026-06-26","ACTUAL",{"date":74,"type":77},{"date":80,"type":62},"2030-12-31",{"name":5,"class":6},1]